Projects per year
Personal profile
Personal profile
Dr. Andrew Farach is an associate professor in the Department of Radiation Oncology at Houston Methodist Hospital. His interest and special procedures are in breast cancer, brain cancer, gynecologic cancer, lung cancer, hepatobiliary cancer, gastrointestinal cancer, lymphoma, brachytherapy, stereotactic radiation/surgery.
Dr. Farach earned his medical degree from Thomas Jefferson University, Jefferson Medical College in Philadelphia. He completed his internship at the University of Texas Health Science Center and his radiation oncology residency training at Baylor College of Medicine. He became Director of Brachytherapy in the Department of Radiation Oncology at Houston Methodist in 2018. Dr. Farach is active in ASTRO (American Society of Therapeutic Radiology and Oncology), ACR (American College of Radiology), and the Texas Radiological Society (TRS). Dr. Farach has published peer-reviewed articles on topics such as SBRT outcomes in lung cancer, radiation and immunotherapy for breast cancer, and liver regeneration after SBRT. He plays an important role in cancer patient care, clinical research and the education of residents and students.
External positions
Associate Professor of Clinical Radiation Oncology, Weill Cornell Medical College
Nov 1 2022 → …
Research Area Keywords
- Imaging & Radiology
- Cancer
- Clinical Translation & Trials
- Clinical Care
Fingerprint
Dive into the research topics where Andrew M. Farach is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase II Clinical tRial of neoADjuVant sAsanlimab and stereotaCtiC body radIatioN thErapy as an in situ vaccine for cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD VACCINE MIBC)
Satkunasivam, R., Chen, S., Esnaola, N. F., Farach, A. M., Teh, B. S. & Zhang, J.
1/20/22 → …
Project: Clinical Trial
-
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination withIntravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVACancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.
Zaid, T., Butler, E. B., Darcourt, J., Farach, A. M., Kamat, A. A., Shkedy, C., Singh, M. & Suri, A.
3/1/14 → 2/28/39
Project: Non Profit
-
NRG-LU005
Zhang, J., Abdelrahim, M., Bernicker, E. H., Chang, J. C., Farach, A. M., Haque, W. M., Heyne, K., Morgan, P. B., Niravath, P. A. & Singh, M.
Project: Clinical Trial
-
GOG0274The OUTBACK Trial
Kamat, A. A., Alaniz, A., Butler, E. B., Farach, A. M., Morgan, P. B., Singh, M. & Suri, A.
Project: Clinical Trial
-
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy (RTOG 0724/GOG-0724 )
Kamat, A. A., Butler, E. B., Farach, A. M., Morgan, P. B., Singh, M. & Suri, A.
Project: Clinical Trial
-
A feasibility study of utilizing a cadaveric training model for novel robotic bladder cancer brachytherapy techniques
Patel, A., Orakwue, C. W., Olek, D., Guzman, J. C. A., Lim, K., Pino, R., Teh, B. S., Butler, B., Satkunasivam, R. & Farach, A., Mar 1 2023, In: Brachytherapy. 22, 2, p. 195-198 4 p.Research output: Contribution to journal › Article › peer-review
-
Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer
Tran, K. T., Chevli, N. C., Messer, J. A., Haque, W., Farach, A. M., Satkunasivam, R., Zhang, J., Darcourt, J., Lo, S. S., Siva, S., Butler, E. B. & Teh, B. S., Mar 2023, In: Clinical and Translational Radiation Oncology. 39, 100592.Research output: Contribution to journal › Article › peer-review
Open Access -
Role of 21-Gene Recurrence Score in Predicting Prognostic Benefit of Radiation Therapy After Breast-Conserving Surgery for T1N0 Breast Cancer
Chevli, N., Haque, W., Tran, K. T., Farach, A. M., Schwartz, M. R., Hatch, S. S., Butler, E. B. & Teh, B. S., May 1 2023, In: Practical Radiation Oncology. 13, 3, p. e230-e238Research output: Contribution to journal › Article › peer-review
Open Access -
21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age ≥ 70 with T1N0 ER/PR + HER2- breast cancer treated with breast conserving surgery and endocrine therapy
Chevli, N., Haque, W., Tran, K. T., Farach, A. M., Schwartz, M. R., Hatch, S. S., Butler, E. B. & Teh, B. S., Sep 2022, In: Radiotherapy and Oncology. 174, p. 37-43 7 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Sun, K., Xu, Y., Zhang, L., Niravath, P., Darcourt, J., Patel, T., Teh, B. S., Farach, A. M., Guerrero, C., Mathur, S., Sultenfuss, M. A., Gupta, N., Schwartz, M. R., Haley, S. L., Nair, S., Li, X., Nguyen, T. T. A., Butner, J. D., Ensor, J., Mejia, J. A., & 5 others, Oct 14 2022, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 28, 20, p. 4392-4401 10 p.Research output: Contribution to journal › Article › peer-review
Open Access